Literature DB >> 19533274

Preoperative evaluation of patients with liver cirrhosis undergoing open heart surgery.

Takashi Murashita1, Tatsuhiko Komiya, Nobushige Tamura, Genichi Sakaguchi, Taira Kobayashi, Tomokuni Furukawa, Akihito Matsushita, Gengo Sunagawa.   

Abstract

OBJECTIVE: Clinical outcomes after open heart surgery in patients with liver cirrhosis are not satisfactory. For evaluating hepatic function, the Child-Pugh classification has been widely used. It has been reported that open heart surgery can be performed safely in patients with mild liver cirrhosis. In this study, we examined the clinical outcomes after open heart surgery in patients with liver cirrhosis and evaluated the usefulness of the Child-Pugh classification.
METHODS: There were 12 liver cirrhosis patients who underwent open heart surgery between January 2002 and December 2006 at our institution. The severity of cirrhosis was graded according to the Child-Pugh classification. We reviewed clinical outcomes, such as postoperative mortality and morbidity, and tried to determine the risk factors. Finally, we assessed the usefulness of the Child-Pugh classification.
RESULTS: Six patients were classified as having Child class A, and the other six patients were classified as B. The overall mortality of group A was 50%, and that of group B was 17%. Postoperative major morbidities occurred in half of the patients of Child class A and in all of the patients of Child class B. Patients who experienced major morbidities had markedly lower levels of serum cholinesterase (106 +/- 46 vs. 199 +/- 72 IU/l; P = 0.02) and lower platelet level (7.5 +/- 2.9 vs. 11.9 +/- 3.6 x 104/microl; P = 0.04).
CONCLUSION: The mortality and morbidity rates were high even in the Child class A patients. The Child classification may be an insufficient method for evaluating hepatic function. We have to assess other factors, such as the serum cholinesterase level or the platelet count.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19533274     DOI: 10.1007/s11748-008-0374-0

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  11 in total

Review 1.  Release of vasoactive substances during cardiopulmonary bypass.

Authors:  S W Downing; L H Edmunds
Journal:  Ann Thorac Surg       Date:  1992-12       Impact factor: 4.330

2.  Early and late outcome after elective cardiac surgery in patients with cirrhosis.

Authors:  P Bizouarn; A Ausseur; P Desseigne; Y Le Teurnier; B Nougarede; M Train; J L Michaud
Journal:  Ann Thorac Surg       Date:  1999-05       Impact factor: 4.330

3.  In vivo estimates of hepatic binding protein concentration: correlation with classical indicators of hepatic functional reserve.

Authors:  M Kudo; D R Vera; R C Stadalnik; W L Trudeau; K Ikekubo; A Todo
Journal:  Am J Gastroenterol       Date:  1990-09       Impact factor: 10.864

4.  Predictive value of preoperative serum cholinesterase concentration in patients with liver dysfunction undergoing cardiac surgery.

Authors:  N Hirata; Y Sawa; H Matsuda
Journal:  J Card Surg       Date:  1999 May-Jun       Impact factor: 1.620

5.  Cardiac operations in patients with cirrhosis.

Authors:  J D Klemperer; W Ko; K H Krieger; M Connolly; T K Rosengart; N K Altorki; S Lang; O W Isom
Journal:  Ann Thorac Surg       Date:  1998-01       Impact factor: 4.330

6.  Cardiac surgery in patients with liver cirrhosis.

Authors:  Cheng-Hsin Lin; Fang-Yue Lin; Shoei-Shen Wang; Hsi-Yu Yu; Ron-Bin Hsu
Journal:  Ann Thorac Surg       Date:  2005-05       Impact factor: 4.330

7.  Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-operative Transfusion (ISPOT) Investigators.

Authors:  A Laupacis; D Fergusson
Journal:  Anesth Analg       Date:  1997-12       Impact factor: 5.108

8.  Open-heart surgery in patients with liver cirrhosis.

Authors:  Yong An; Ying-Bin Xiao; Qian-Jin Zhong
Journal:  Eur J Cardiothorac Surg       Date:  2007-02-20       Impact factor: 4.191

9.  Impairment of hepatosplanchnic oxygenation and increase of serum hyaluronate during normothermic and mild hypothermic cardiopulmonary bypass.

Authors:  Nobuhiro Okano; Sotaro Miyoshi; Ryoichi Owada; Nao Fujita; Yuji Kadoi; Shigeru Saito; Fumio Goto; Toshihiro Morita
Journal:  Anesth Analg       Date:  2002-08       Impact factor: 5.108

10.  Clinical outcome after cardiac operations in patients with cirrhosis.

Authors:  Nobuhiko Hayashida; Takahiro Shoujima; Hideki Teshima; Yoshinori Yokokura; Kazuyoshi Takagi; Hiroshi Tomoeda; Shigeaki Aoyagi
Journal:  Ann Thorac Surg       Date:  2004-02       Impact factor: 4.330

View more
  5 in total

1.  Increased serum Wisteria floribunda agglutinin positive Mac-2 binding protein (Mac-2 binding protein glycosylation isomer) in chronic heart failure: a pilot study.

Authors:  Atsushi Okada; Hideaki Kanzaki; Yasuhiro Hamatani; Seiji Takashio; Hiroyuki Takahama; Makoto Amaki; Takuya Hasegawa; Yasuo Sugano; Satoshi Yasuda; Toshihisa Anzai
Journal:  Heart Vessels       Date:  2017-11-02       Impact factor: 2.037

Review 2.  Influence of cirrhosis in cardiac surgery outcomes.

Authors:  Juan C Lopez-Delgado; Francisco Esteve; Casimiro Javierre; Josep L Ventura; Rafael Mañez; Elisabet Farrero; Herminia Torrado; David Rodríguez-Castro; Maria L Carrio
Journal:  World J Hepatol       Date:  2015-04-18

3.  Liver dysfunction as an important predicting risk factor in patients undergoing cardiac surgery: a systematic review and meta-analysis.

Authors:  Wan Chin Hsieh; Po Chen Chen; Flavia-Catalina Corciova; Grigore Tinica
Journal:  Int J Clin Exp Med       Date:  2015-11-15

4.  Results of cardiac surgery in advanced liver cirrhosis.

Authors:  Naoto Morimoto; Kenji Okada; Yutaka Okita
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-11-01

5.  Low serum cholinesterase predicts complication risk after orthopedic surgery in elderly patients: an observational pilot study.

Authors:  Mitsuhiro Matsuo; Tohru Yamagami
Journal:  JA Clin Rep       Date:  2019-06-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.